View Item 

Show simple item record

Treatment of hepatitis B
dc.contributor.authorLok, Anna Suk-Fongen_US
dc.contributor.authorWai, Chun-Taoen_US
dc.date.accessioned2006-09-08T20:20:40Z
dc.date.available2006-09-08T20:20:40Z
dc.date.issued2002-10en_US
dc.identifier.citationWai, Chun Tao; Lok, Anna S. F.; (2002). "Treatment of hepatitis B." Journal of Gastroenterology 37(10): 771-778. <http://hdl.handle.net/2027.42/42442>en_US
dc.identifier.issn0944-1174en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/42442
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12424559&dopt=citationen_US
dc.description.abstractChronic hepatitis B virus (HBV) infection affects approximately 350 million people worldwide. Treatment of chronic hepatitis B is aimed at sustained suppression of HBV replication and remission of liver disease. Currently, antiviral treatment is indicated for hepatitis B e antigen (HBeAg)-positive patients in the immune clearance phase, and for HBeAg-negative patients with evidence of active liver disease and continued high levels of HBV replication. Treatment is not recommended for patients in the immune tolerance phase or the inactive carrier state, due to lack of efficacy of current treatment. This review updates safety and efficacy data of interferon alpha and lamivudine in the treatment of chronic hepatitis B. Management strategies in different clinical scenarios and future treatments are also discussed.en_US
dc.format.extent70466 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherSpringer-Verlag; Springer-Verlag Tokyoen_US
dc.subject.otherLegacyen_US
dc.subject.otherLamivudineen_US
dc.subject.otherKey Words: Chronic Hepatitis Ben_US
dc.subject.otherInterferon Alphaen_US
dc.subject.otherTreatmenten_US
dc.titleTreatment of hepatitis Ben_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109-0362, USA, USen_US
dc.contributor.affiliationumDivision of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109-0362, USA, USen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid12424559en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/42442/1/20370771.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/s005350200129en_US
dc.identifier.sourceJournal of Gastroenterologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
20370771.pdf
Size:
68.81KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.